The U.S. Food and Drug Administration (FDA) has approved the first generic form of the blood thinner Lovenox (enoxaparin sodium) for the treatment of deep vein thrombosis. Lovenox is made from the blood-thinning medication heparin. FDA officials report that about 100,000 cases of pulmonary embolism due to deep vein thrombosis are reported each year in the United States, making it the third-most common cause of death among people in hospitals.
Read moreI’ve grown a new appreciation for people who have to give themselves shots on a daily basis. Yes, I mean shots with needles. Many of... Read more »
The anti-cancer properties of garlic were first recognized in the 1950's when scientists linked allicin, a principal component of garlic,... Read more »
Despite the rain here in West Virginia, Halloween brought out dozens of trick-or-treaters to my neighborhood. There were skeletons,... Read more »
The plan was simple and well thought out by my three doctors. My pregnancy was considered high-risk because of my history of stroke. So,... Read more »
It's been seven weeks since I had my baby. The time is really flying by and soon my maternity leave will be over. I've been slowly... Read more »
Stroke patients who suffer from paralysis are helped more by Lovenox than heparin, a new study suggests. Researchers gave 1,762 stroke patients who... Read more »
The U.S. Food and Drug Administration (FDA) has given priority review status to Lovenox for the treatment of acute heart attack. The FDA grants... Read more »
The U.S. Food and Drug Administration has given expanded approval for the blood thinner Lovenox to treat the most severe form of heart attack. The... Read more »
Source: ADAM Encyclopedia
A parathyroid biopsy is the removal of a small piece of a parathyroid gland for examination under a microscope. The parathyroid glands are found just... Read more »
Source: eOrthopod
Any one who has had a total hip or total knee replacement knows that a major concern after surgery is the formation of blood clots. Blood clots can... Read more »